Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia.

MLA

Muppidi, Monica R., et al. “Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia.” Clinical Lymphoma, Myeloma & Leukemia, vol. 15 Suppl, June 2015, pp. S73–79. EBSCOhost, https://doi.org/10.1016/j.clml.2015.02.033.

APA

Muppidi, M. R., Portwood, S., Griffiths, E. A., Thompson, J. E., Ford, L. A., Freyer, C. W., Wetzler, M., & Wang, E. S. (2015). Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma & Leukemia, 15 Suppl, S73–S79. https://doi.org/10.1016/j.clml.2015.02.033

Chicago

Muppidi, Monica R, Scott Portwood, Elizabeth A Griffiths, James E Thompson, Laurie A Ford, Craig W Freyer, Meir Wetzler, and Eunice S Wang. 2015. “Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia.” Clinical Lymphoma, Myeloma & Leukemia 15 Suppl (June): S73–79. doi:10.1016/j.clml.2015.02.033.